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The purpose of  the present study was to investigate and compare the effects of  two 
ruthenium complexes with trifl uoperazine on acethylcholinesterase enzyme activity 
and lactate dehydrogenase levels in vivo under physiological conditions in rats blood. 
Complexes 1 and 2 showed positive effects on acethylcholinesterase at all doses and 
did not disturb its normal activity. Total LDH activity was inhibited in the presence 
of  both complexes, but Ru(II) complexes showed different effects on the activity of  
LDH isoenzymes. The activities of  LDH1 and LDH2 isoenzymes were decreased in all 
applied doses of  the complex 2, while the activity of  LDH2 reduced using complex 1 in 
the same doses. Results of  the present study suggest the neuro- and cardio protective 
potential of  oral administration of  complexes 1 and 2, as non-toxic compounds 
under physiological conditions. These protective effects are the result of  their potent 
antioxidant activity.
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INTRODUCTION
Metal complexes of  ruthenium have been for more than twenty years in the focus 
of  many researches in chemistry [1-4] as well as in medicine [5,6]. Their properties 
can be altered by the choice of  ligands, which means that complexes potentially have 
multiple applications. Ruthenium complexes show an antimicrobial activity [5,7] but 
their most interesting activity is on tumor cells [8-10] with developed resistance to the 
usual medicinal treatment, including cisplatin. The advantage of  ruthenium complexes 
is their relatively low toxicity [6,11], lower than cisplatin, which can partly be explained 
by its reduced reactivity to DNA in intact cells. Many biological properties have 
been attributed to ruthenium complexes including antioxidant activity [12,13] and 
cytotoxicity [3,9,10]. Anticancer activities of  Ru(II)-DMSO complexes are known for 
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many years and some of  them are in intensively clinical trials [14,15], while Ru(II)-
arene complexes have been also widely studied as anticancerogenic compounds [3,16]. 
Previous investigations of  enzyme activities of  ruthenium complexes demonstrated 
a slight induction of  superoxide dismutase (SOD) and catalase (CAT) in the rat liver 
tissue [17], but also an inhibition of  succinate dehydrogenase (SDH) and cytochrome 
oxidase (COX) activities in the brain, heart, skeletal muscle, liver and kidney of  rats 
[18]. Ruthenium(II) and ruthenium(III) complexes exhibit antioxidative enzyme 
activities (SOD, CAT) and might be responsible for complex–induced cytotoxicity 
[19]. Expression of  lactate dehydrogenase (LDH) isoenzymes and tumors was 
investigated [20] and it was found that inhibition of  LDH can be considered one of  
the ways to control tumor growth [21]. Ruthenium complexes have a good cytotoxic 
effect and their possible applications as non-competitive inhibitors of  LDH were 
reported [22,23]. Ru(II) complexes can decrease total levels of  serum LDH and LDH4 
in tumor cells, as well as increase serum glutamate oxaloacetate transaminase (SGOT) 
activity, without toxic effects on the liver [23]. A relationship between the increase 
of  acethylcholinesterase and apoptosis of  tumor cells was also reported [24,25]. 
Acetylcholinesterase (AChE) is a hydrolase in the nervous system that plays a key role 
in cholinergic transmission by catalyzing the rapid hydrolysis of  the neurotransmitter 
acetylcholine (ACh) [26]. This enzyme was identifi ed in the amyloid plaques found in 
Alzheimer’s disease and the isoforms of  AChE have different effects on the extent of  
plaque development [27].
Among the numerous drugs reported, phenothiazine and its N–alkyl derivatives 
are specifi c. Phenothiazines are sulpfur- and nitrogen-containing tricyclic aromatic 
compounds, famous as dyes in the middle of  the nineteen century, after what they 
found their application in pharmacy and medicine as antipsychotic, antihistaminic, 
antiemetic and analgetic drugs [5, 28]. In the literature are described few mononuclear 
complexes with phenothiazines as ligands coordinated in a monodentate fashion 
through heterocyclic sulfur [29-31] or through heterocyclic nitrogen [32]. Despite 
the description of  synthetic derivatives with transition metals [33,34], only partial 
biological activities of  these compounds were tested. 
New Ru(II)-DMSO and Ru(II)-p-cymene complexes with N-alkylphenothiazines were 
previously synthesized and characterized by elemental analysis and spectroscopic 
methods (FT-IR, UV-Vis, 1H and 13C NMR) [35,36]. These complexes showed effects 
on antioxidative enzymes, as well as malondyaldehyde and nitrite levels in rats blood. 
Therefore, in vitro cytotoxic activity of  complexes was assayed in four human carcinoma 
cell lines MCF-7, MDA-MB-453 (breast carcinoma), SW-480 (colon carcinoma) and 
IM9 (myeloma multiple cells).
In continuation of  our previous research [35,36], the aim of  the present study was 
to investigate the effect of  two ruthenium complexes with trifl uoperazine, previously 
prepared and characterized in our laboratory (Scheme 1), on acethylcholinesterase 
enzyme activity in rats blood as well as their ability to infl uence LDH levels in vivo 
under physiological conditions. 




All reagents and chemicals were purchased from commercial sources. Enzyme activities 
were measured on CECIL CE 2021 UV/VIS spectrophotometer, while electrophoresis 
was performed on a vertical device Mini Ve Hoffer, LKB 2117, Bromma, Uppsala, 
Sweden. The band intensities of  the isoenzymes of  LDH were estimated using Scion 
Image Beta 4.02 software for Windows. 
The complex (TF.2H)Ru(DMSO)3Cl3Cl·0.5C2H5OH (1) was prepared by the 
reaction of  complex RuCl2(DMSO)4 and trifl uoperazine dihydrochloride (TF.2HCl) 
in absolute ethanol [35]. In the reaction the starting complex RuCl2(6-p-cymene)2 
with TF.2HCl in 2-propanol as solvent, complex 2 (TF.2H)RuCl3(6-p-cymene)
Cl·0.5C3H7OH·0.5H2O was synthesized [36]. Both complexes were characterized by 
elemental analysis, spectroscopic methods and x-ray diffraction as previously described 
[35,36].
Biological assays
The experiments were carried out on adult male Wistar rats (200–300 g) housed in 
stainless steel cages with wired fl oors and with free access to food and water, in a 
room under controlled conditions (12 h light–dark cycle, temperature 22 ± 2 °C). Rats 
were randomly assigned to an experimental or to the control group. All experiments 
were done according to our institutional guidelines for animal research and principles 
of  the European Convention for the Protection of  Vertebrate Animals Used for 
Sheme 1. General formulae of  complexes: (TF.2H)Ru(DMSO)3Cl3Cl·0.5C2H5OH (1) 
and (TF.2H)RuCl3(6-p-cymene)Cl·0.5C3H7OH·0.5H2O (2), where TF.2H is protonated 
trifl uoperazine
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Experimental and Other Scientifi c Purposes (Offi cial Daily N. L 358/1-358/6, 18, 
December 1986).
Rats were divided into seven groups of  eight animals each: the control (group I), and 
three separate groups for each compound treated i.p. with complexes dissolved in 
water, at doses of  0.4 μmol kg-1 bw (group II), 4.5 μmol kg-1 bw (group III) and 90.4 
μmol kg-1 bw (group IV). Blood samples (6-8 ml) were obtained via aorta abdominalis 
puncture (from all rats, including the control group, 24 h after treatment) and collected 
in tubes containing sodium-citrate (3.8% w/v) as anticoagulant. Erythrocytes and 
plasma were separated by centrifugation (3000 rpm), then the erythrocytes were 
washed in saline solution three times, and the enzymes activities were determined 
immediately.
Determination of AChE activity in erythrocytes 
AChE activity was determined as described at an earlier date [37]. The principle of  the 
method is the measurement of  the production rate of  thiocholine as acetylthiocholine 
is hydrolyzed. This is accomplished by the continuous reaction of  the thiol with 
5,5’-dithiobis-2-nitrobenzoate ion to produce the yellow anion of  5-thio-2-nitro-
benzoic acid. The rate of  color production is measured at 412 nm. Activity was 
expressed as U/g Hb.
Determination of LDH activity in plasma
The total LDH activity in plasma was determined spectrophotometically according to 
the method of  McQueen [38]. In the reaction between sodium piruvate and NADH 
at pH 7.2 lactate is formed, which reacts with the enzyme from the plasma.The activity 
of  LDH is determined by the decrease in absorbance at 340 nm and expressed as U/
mg proteins.
LDH isoenzymes (LDH1-5) were detected by vertical electrophoresis on non-denaturing 
7% PAGE using a Tris-glycine buffer, following the methods described [39]. The 
isoenzymes bands were detected using lithium lactate as a substrate in the presence 
of  cofactors NADH and tetrazolium blue. The color intensity of  each isoenzyme 
strip was measured by densitometry. The density of  each band was estimated with 
respect in percent to the total area. The band intensities of  the LDH isoenzymes were 
estimated using Scion Image Beta 4.02 software [40].
Statistical analysis
Data are expressed as the means ± SD. Statistical signifi cance was tested by one-way 
Anova followed by Dunnett’s t-test. The minimum level of  statistical signifi cance was 
set to p < 0.05.
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RESULTS
The AChE activity was signifi cantly increased (p < 0.01) by using 4.5 and 90.4 μmol 
kg-1 bw of  complex 1 as present in Fig. 1a. The effect of  complex 2 on AChE activity 
in erythrocytes was different and signifi cantly higher in all applied doses compared to 
the control group (Fig. 1b). Therefore, almost the same effect was noticed using lower 
doses of  complex 2 (0.4 and 4.5 μmol kg-1 bw). A signifi cant increase of  AChE activity 
with 90.4 μmol kg-1 bw complex 2 was also observed.
The present study demonstrated that the ruthenium(II) complexes inhibited total LDH 
activity in all applied doses compared to the control group, however the difference was 
not statistically signifi cant (p < 0.05) (Fig. 2).
The effects of  ruthenium(II) complexes on the activity of  LDH isoenzymes are here 
presented (Table 1 and 2). Complex 1 reduced the activity of  LDH2 isoenzyme at all 
applied doses, while it signifi cantly increased (p < 0.01) LDH1 isoenzyme activity in 
Figure 2. Total LDH activity: I–control group; II – rats treated i.p. with complexes at a dose of  
0.4 μmol kg-1 bw; III – rats treated i.p. with complexes at a dose of  4.5 μmol kg-1 bw; IV – rats 
treated i.p. with complexes at a dose of  90.4 μmol kg-1 bw, a) for complex 1 and b) complex 2
Figure 1. AChE activities in rats erythrocytes: I– control group; II – rats treated i.p. with 
complexes at a dose of  0.4 μmol kg-1 bw; III – rats treated i.p. with complexes ata  dose of  
4.5 μmol kg-1 bw; IV – rats treated i.p. with complexes at a dose of  90.4 μmol kg-1 bw, a) for 
complex 1 and b) complex 2; Hb: Haemoglobin
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a dose of  4.5 μmol kg-1 bw (group III) (Table 1). The activity of  LDH3 isoenzyme 
increased linearly with increasing doses of  complex 1, but the difference was not 
statistically signifi cant. A dose of  0.4 μmol kg-1 (group II) induced a stronger positive 
effect on LDH1, while doses of  4.5 and 90.4 μmol kg
-1 of  complex 1 had a negative 
infl uence and signifi cantly increased (p < 0.05) the activity of  LDH4 and  LDH5, 
respectively.














I 40.11 ± 3.41 37.28 ± 5.88 9.34 ± 2.49 7.07 ± 2.36 3.23 ± 2.05
II 33.59 ± 7.09** 27.34 ± 14.75 9.94 ± 4.12 17.29 ± 13.49 4.85 ± 2.77
III 47.20 ± 4.87*** 20.38 ± 12.62*** 11.67 ± 3.77 12.92 ± 4.96** 4.61 ± 2.71
IV 42.69 ±2.54 17.93 ± 6.64*** 15.94 ± 7.15 12.26 ± 2.53 8.35 ± 4.09**
Values are expressed as mean ± SD. Signifi cantly different from  I group (control) for the same isoenzyme 
***p < 0.01, ** p < 0.05
The infl uence of  complex 2 on LDH activity is given in Table 2. Complex 2 caused 
a signifi cant decline in the activity of  LDH2 in all treated groups with signifi cant 
inhibition (p < 0.05) at doses of  4.5 μmol kg-1 (group III) and 90.4 μmol kg-1 (group 
IV) (Table 2). A signifi cant increase (p < 0.05) was also observed in the activity of  
LDH4 (group treated with 0.4 μmol kg
-1 bw), LDH3 (group treated with 4.5 μmol kg
-1 
bw) and LDH5 (group treated with 90.4 μmol kg
-1 bw). A dose of  4.5 μmol kg-1 (group 
III) induced a very positive effect on LDH2, while a dose of  90.4 μmol kg
-1 had a 
negative infl uence and increased the activity of  LDH5. 














I 38.78 ± 3.15 35.86 ± 6.29 10.64 ± 2.62 8.08 ± 4.54 5.30 ± 3.81
II 37.98 ± 3.21 29.90 ± 8.50 10.88 ± 3.29 16.44 ± 5.48** 7.15 ± 1.40
III 38.04 ± 7.60 20.98 ± 9.84** 16.03 ± 3.59** 15.18 ± 8.45 9.93 ± 5.05
IV 35.30 ± 3.53 23.54 ± 9.95** 10.27 ± 2.91 11.87 ± 4.85 16.29 ± 5.98**
Values are expressed as mean ± SD. Signifi cantly different from  I group (control) for the same isoenzyme 
** p < 0.05
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DISCUSSION
Reactive oxygen species (ROS) are involved in many biochemical processes in living 
organisms. Small amounts of  ROS, including hydroxyl radicals (•OH), superoxide 
anions (O2
•-) and hydrogen peroxide (H2O2) are constantly generated in aerobic 
organisms. Their low levels are vital for a number of  cell signaling events and they 
are essential for proper cell function. Otherwise,  high concentrations of  ROS result 
in oxidative stress and as a result damage the biological macromolecules. To protect 
against oxidative damage, organisms developed a variety of  antioxidant defenses that 
include specialized antioxidant enzymes as superoxide dismutase (SOD), glutathione 
peroxidase (GPX) and catalase (CAT). Ruthenium(II) complexes showed effects on 
the activity of  antioxidative blood enzymes (SOD and CAT) in rats treated i.p. with 
complexes at three different doses: 0.4, 4.5 and 90.4 μmol kg-1 bw [35,36]. 
The biological effect of  these Ru(II) complexes were investigated. AChE activity as 
a parameter of  their infl uence on brain function was tested. Acetylcholinesterase is 
an enzyme present in the nervous tissue, muscle and erythrocytes that catalyzes the 
hydrolysis of  acetylcholine to choline and acetic acid. This enzyme is present throughout 
the body, but the activity of  AChE is higher in motor than sensor neurons. Inhibition of  
AChE leads to accumulation of  acetylcholine in the synapses, signaling is interrupted, 
which results in dysfunctioning nerve impulses. Many diseases are connected to the 
inhibition of  AChE, as myasthenia gravis, Parkinson’s and Alzheimer’s diseases [41]. 
Both complexes showed a strong positive effect at the highest dose (4.5 and 90.4 
μmol kg-1 bw), while applied in 4.5 μmol kg-1 bw complex 1 increased AChE activity 
more than complex 2. Conversely, a better effect on AChE complex 2 was shown at 
lower doses compared to complex 1. As it is well known, the activity of  AChE is in 
correlation with apoptosis of  cancer cells and these results agree with cytotoxic effects 
of  complexes 1 and 2 [35,36]. 
The disturbance of  the cell membrane integrity causes an increase in the extracellular 
concentration of  big macromolecules, such as LDH. Lactate dehydrogenase is a 
tetrameric cytoplasmatic enzyme present in almost all major organs. Its role in the 
metabolism is to catalyse the oxidation of  L-lactate to pyruvate as the fi nal step in the 
metabolic chain of  anaerobic glycolysis. Four peptide chains form two types of  lactate 
dehydrogenase: heart (H) subunit or muscle (M) subunit, which are so named because 
of  their predominance in the respective tissues. LDH has fi ve different isoenzyme 
forms which catalyze the same biochemical reaction but differ in their molecular 
structure, and organ specifi city. The isoenzymes are separable by electrophoresis. The 
subunit compositions of  fi ve isoenzymes, in order of  decreasing anodal mobility in 
an alkaline medium are: LDH1 and LDH2 (found primarily in the heart and red blood 
cells), LDH3 (kidneys and brain), LDH4 (lung and spleen) and LDH5 (dominantly in 
the liver and muscle) [42]. Determination of  the isoenzyme forms of  this enzyme 
enables us to defi ne the type and the level of  cell damage in some tissues [43].
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Total LDH activities were reduced by both ruthenium complexes, compared to the 
activity of  this enzyme in the control group. Complex 1 slightly decreased total LDH 
activity with increasing applied doses. In the case of  complex 2 the biological effect 
was the opposite. Complex 2 caused an increase of  total enzyme activity from 0.4 to 
90.4 μmol kg-1 bw, but without a signifi cant difference (p < 0.05).
Complex 1 decreases the activity of  LDH2 isoenzyme in all applied doses, while the 
activities of  the LDH1 and LDH4 are increased if  complex 1 is applied at a dose of  
4.5 μmol kg-1 bw. These results are in agreement with previous studies [22] and show 
a strong inhibition of  LDH isoenzymes induced by Ru(II)-DMSO complex. Both 
complexes show a signifi cant increase in the activity of  LDH5 in the highest applied 
dose, which may suggest potential hepatotoxic effects, but at the same time these 
doses of  complexes signifi cantly reduce activity of  LDH2 primarily from red blood 
cells. The activity of  LDH1 isoenzyme is decreased at all applied doses of  complex 
2, while the effect of  this complex on LDH4 and LDH5 shows an increase of  their 
activities (Fig. 3). This study clearly demonstrates that LDH isoenzymes are sensitive 
to all applied doses of  the investigated Ru(II)complex.
An important effect of  LDH activity inhibition is the decrease anaerobic glycolysis 
in cells which is crucial for the growth of  tumor cells. Earlier researches [23,44] have 
shown that metal complexes can bind to LDH and thus reduce its activity or change the 
conformation of  the enzyme. Ru(II) complexes 1 and 2 reduce total LDH, probably in 
a similar fashion, which can be connected with previously proved cytotoxicity [35,36]. 
In summary, biological assays of  Ru(II) complexes with Nalkylphenothiazine ligands 
provide clear evidence that complex 1, under physiological conditions can increase 
the activity of  AChE at higher doses, while complex 2 has a positive infl uence at 
all applied doses. These results suggest that the complexes do not lead to enhanced 
production of  acetylcholine and thus do not cause neuromuscular diseases.
Results of  LDH isoenzymes activities measuring exhibit different sensitivity, depending 
on the applied concentration of  the complexes 1 and 2, but also a positive effect on 
the heart muscle due to the decreased activity of  isoenzymes LDH2 with increasing 
Figure 3. Electrophoresis of  LDH isoenzymes on non-denaturing 7% PAGE: 1-5– control 
group; 6-10 – rats treated i.p. with complex 2 at a dose of  0.4 μmol kg-1 bw; 11-15 – rats treated 
i.p. with complex 2 at a dose of  4.5 μmol kg-1 bw; 16-20 – rats treated i.p. with complex 2 at a 
dose of  90.4 μmol kg-1 bw
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concentration of  these complexes, compared to the control group. Also, complex 
1 does not damage the brain tissue (LDH3 is not signifi cant increased, while AChE 
activity signifi cantly increased), while both complexes show positive effects on liver in 
lower doses (LDH5). 
Results of  the present study suggest the neuro- and cardioprotective potential of  
orally administered complexes 1 and 2, as non-toxic compounds under physiological 
conditions, induced through its potent antioxidant activity. This investigation confi rms 
a great potential of  Ru(II)-cymene complexes as pharmacological drugs and potential 
biological compounds with promising applications. The whole mechanism of  infl uence 
of  Ru(II) complexes on cancer cells via anaerobic glycolysis will be the subject of  our 
future research.
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IN VIVO ISPITIVANJE ENZIMSKE AKTIVNOSTI NEKIH Ru(II) 
JEDINJENJA SA N-ALKILFENOTIAZINIMA
KRSTIĆ P. Milena,  BOROZAN Z. Sunčica, SOVILJ P. Sofi ja, GRGURIĆ-ŠIPKA R. 
Sanja, POLJAREVIĆ M. Jelena
Cilj ovog rada je da se ispitaju i uporede efekti dva kompleksa rutenijuma sa 
trifl uoperazinom na aktivnost enzima acetilholinesteraze i laktat-dehidrogenase in 
vivo pod fi ziološkim uslovima u krvi pacova. Kompleksi 1 i 2 pokazali su pozitivan 
efekat na aktivnost acetiholinesteraze u svim primenjenim dozama. Ukupna aktivnost 
LDH je inhibirana u prisustvu oba kompleksa, ali kompleksi Ru(II) pokazuju različite 
rezultate na izoenzimske oblike ovog enzima. Aktivnosti izoenzima LDH1 i LDH2 
su smanjene u svim primenjenim dozama kompleksa 2, dok kompleks 1 smanjuje 
aktivnost samo izoenzima LDH2 u tim istim koncentracijama. Rezultati prikazanog 
istraživanja ukazuju na neuro - i kardio zaštitni potencijal oralne primene kompleksa 1 
i 2, kao netoksičnih jedinjenja pod fi ziološkim uslovima, indukovano preko njihovog 
snažnog antioksidativnog efekta.
